Issue № 25 | 2016 (3)
The funding of drug treatment of socially significant diseases is a part of the Program on State Guarantees of Free Medical Care for Russian Citizens, and one of the priorities for the Ministry of Health of the Russian Federation. The efficient use of budget funds allocated for drug supply of patients is one of the most complicated and hard-to-solve problems for decision-makers at all levels of health care management. Health officials need to create evidence-based and transparent tools of complex clinical and economic assessment of the cost of illness, to define the advisability of specific medical technologies, and to obtain high-quality economic calculations. These tasks can be solved by pharmacoeconomic simulation. In the present study, we used such simulation to choose drug therapy of advanced and metastatic forms of neuroendocrine tumors. The following results were obtained. Direct costs of laboratory and instrumental examination were 102,992 RUB per patient; the costs of a standard dose (30 mg) octreotide ranged from 616,066 to 1,090,671 RUB annually depending on the brand and route of administration. Increased doses of octreotide (up to 40 mg monthly) needed in routine clinical practice required 732,305 RUB per patient (Octreotide Depot) or 940,896 RUB per patient (Octreotide-Long FS). 60 mg dose of these drugs would require 945,302 RUB and 1,226,016 RUB per patient, espectively. The cost of 120 mg Lanreotide were 780 000 RUB per patient; this is comparable with the cost of octreotide, which is on the Russian List of Vital and Essential Drugs.
neuroendocrine tumors, diagnostics, treatment, direct cost.
Zelenova O. V., Emelyanova G. S, Zhilina V. V., Kreknina E. A. Clinicoeconomic Feasibility of Somatostatin Analogs for Neuroendocrine Gastrointestinal Tract and Pancreas Tumors Treatment. Medical Technologies. Assessment and Choice. 2016; 3(25): 78–87.